TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Corticosteroid Intra-articular Injection in Hands Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hand OA~* Age over 40~* Visual analogic scale (VAS) for pain at rest between 3-8cm~* Signed informed consent term~Exclusion Criteria:~* Change in the use of oral corticosteroid or nonsteroidal antiinflammatory (NSAID) in the last 30 days~* Change in drugs for OA in the last two months~* IAI in this joints in the last three months~* Any change in treatment for OA in the hands in the last two months~* Suspicion of local and or systemic infection, and pregnancy~* Hands X-ray suggesting arthropathy of the interphalanges of other etiology~* Serious coagulation disorder

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IAI triamcinolone hexacetonide (Type: EXPERIMENTAL): Intra-articular injection with corticosteroid . The study group was called triamcinolone hexacetonide / lidocaine (TH / LD) and a control group, called lidocaine (LD).~Patients in TH / LD group underwent corticosteroid IAI scheme in its most symptomatic interphalangeal (IP) joint composed with triamcinolone hexacetonide(TH) (20mg/ml) and 2% lidocaine without vasoconstrictor. The IAI was realized in the 0.3 ml dose (6mg) of TH for PIP and 0.2 ml (4 mg) of HT for DIP, always associated with 0.1 mL of 2% lidocaine. Paracetamol 750 mg / tablet were also used if required during the 12 weeks of follow-up (up to 03 tablets per day).
- IAI lidocaine (Type: PLACEBO_COMPARATOR): Intra-articular injection with lidocaine. The LD group patients underwent IAI with only 2% lidocaine without vasoconstrictor in its most symptomatic IP joint. Paracetamol 750 mg / tablet were also used if required during the 12 weeks of follow-up (up to 03 tablets per day) . Both groups of patients underwent only one IAI in the most symptomatic joint and on a single occasion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has diagnosis of chronic plaque psoriasis for at least 6 months before the baseline visit.~* Participant meets following disease activity criteria:~* Stable moderate to severe chronic plaque psoriasis, defined as greater than or equal to 10% body surface area (BSA) psoriasis involvement, static physician global assessment (sPGA) score of greater than or equal to 3, and Psoriasis Area Severity Index (PASI) greater than or equal to 12 at Screening and baseline visit.~* Candidate for systemic therapy as assessed by the investigator.~Exclusion Criteria:~* Participant has history of active skin disease other than psoriasis that could interfere with the assessment of psoriasis.~* Participant has history of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis.~* Participant has previous exposure to risankizumab.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Risankizumab (Type: EXPERIMENTAL): Subcutaneous (SC), self-administered 150 mg doses of risankizumab at Weeks 0, 4, and 16
- Placebo (Type: PLACEBO_COMPARATOR): Subcutaneous (SC), self-administered doses of placebo solution at Weeks 0, 4, and 16

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/= 18 years of age~* Histologically or cytologically documented, inoperable, locally advanced, recurrent or metastatic (Stage IIIB or Stage IV) lung adenocarcinoma~* Non-small cell lung cancer with an EGFR activating mutation~* Patients must have evidence of disease, but measurable disease is not mandatory~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Adequate renal and liver function~Exclusion Criteria:~* Prior chemotherapy or other systemic anti-cancer treatment. Neoadjuvant/adjuvant chemotherapy is allowed if completed within 6 months prior to enrolment. Prior radiochemotherapy is allowed if completed more than 6 months before start of study treatment~* Prior therapy with systemic anti-tumour therapy with HER1/EGFR inhibitors~* Any other malignancies within 5 years, except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin carcinoma~* Brain metastasis or spinal cord compression not yet definitely treated with surgery and/or radiation~* Patients unable to take oral medication or requiring intravenous alimentation, with prior surgical procedures affecting absorption or active peptic ulcer disease~* Any significant ophthalmologic abnormality, especially those likely to increase the risk of corneal epithelial lesions; the use of contact lenses is not recommended during the study~* Pregnant or breast-feeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PEAK PlasmaBlade™ vs. Traditional Electrosurgery in Abdominoplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 25 and 60 years old~2. Physically healthy, stable weight, non-smoker~3. Protruding abdomen, excess fat and skin and/or weak abdominal muscles qualifying for abdominoplasty.~4. Subject must understand the nature of the procedure and provide written informed consent prior to the procedure.~5. Subject must be willing and able to comply with specified follow-up evaluations.~6. Female subjects must either be no longer capable of reproduction or taking acceptable measures to prevent pregnancy during the study, and have a negative pregnancy test prior to participation in the study.~Exclusion Criteria:~1. Age younger than 25 or greater than 60 years old~2. Anticoagulation therapy which cannot be discontinued~3. Smoking (any kind)~4. Diabetes (any type)~5. Infection (local or systemic)~6. Cognitive impairment or mental illness~7. Severe cardiopulmonary deficiencies~8. Known coagulopathy~9. Immunocompromised~10. Kidney disease (any type)~11. Subjects who are pregnant or lactating~12. Currently taking any medication known to affect healing~13. Subjects who are status-post gastric banding or gastric bypass~14. Reproductive age females who will not take acceptable measures to prevent pregnancy during the study.~15. Recent history of abdominal surgery or prior abdominoplasty.~16. Subjects who are known to be HIV or Hepatitis (any) positive~17. Currently enrolled in another investigational device or drug trial~18. Unable to follow instructions or complete follow-up

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- PEAK PlasmaBlade (Type: EXPERIMENTAL): The PEAK PlasmaBlade will be used for the abdominoplasty procedure.
- Standard of Care (SOC) (Type: ACTIVE_COMPARATOR): The scalpel and electrocautery will be used for the abdominoplasty procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PREMILOC Trial to Prevent Bronchopulmonary Dysplasia in Very Preterm Neonates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age between 24 weeks and 27 weeks + 6 days~* Babies born to mother with either clinical chorioamnionitis, preterm and prelabor rupture of the membranes (PPROM), or preterm labor~* Written informed consent obtained before inclusion and randomization.~Exclusion Criteria:~* Babies born to mothers with birth weight below the 3th percentile~* PPROM before 22 weeks~* Major fetal anomaly or congenital malformation~* Mother refusal or inability to provide consent.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 24 Hours
- Healthy Volunteers: f

Study Arms:
- 1: hydrocortisone (Type: EXPERIMENTAL): 1: active arm treated with low doses of HC during the first 10 days of life
- 2: Placebo (Type: PLACEBO_COMPARATOR): 2:placebo arm treated with placebo at the same conditions than active arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Before Surgery:~  * Participant scheduled to undergo a primary unilateral bunionectomy with distal first metatarsal osteotomy (i.e., Austin procedure) and internal fixation under regional anesthesia (Mayo and popliteal sciatic block)~* After Surgery:~  * Participant is lucid and able to follow commands~ * All analgesic guidelines were followed during and after the bunionectomy~Key Exclusion Criteria:~* Before Surgery:~  * Prior history of bunionectomy or other foot surgery on the index foot~ * History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)~ * Any prior surgery within 1 month before the first study drug~* After Surgery:~  * Participant had a Type 3 deformity requiring a base wedge osteotomy or concomitant surgery such as hammertoe repair, or had medical complications during the bunionectomy that, in the opinion of the investigator, should preclude randomization~Other protocol defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- VX-548 (Type: EXPERIMENTAL): Participants will be randomized to receive different dose levels of VX-548.
- Hydrocodone bitartrate/acetaminophen (HB/APAP) (Type: ACTIVE_COMPARATOR): Participants will receive HB/APAP.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebos matched to VX-548 and HB/APAP.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Acitretin Plus Pioglitazone in Patients With Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with chronic plaque type psoriasis having body surface area involvement of \> 20%~* Patients of either sex~* Females who have completed their family and are tubectomized or are postmenopausal i.e. no menstrual bleeding over at least 1 year~* Age range 18-65 years~Exclusion Criteria:~* Females of child bearing potential~* H/O hypersensitivity to acitretin~* Impaired hepatic function (serum bilirubin, AST, ALT and alkaline phosphatase \>1.5 times the upper limit of normal)~* Impaired renal function (serum creatinine \>1.5mg% in males and \>1.4 mg% in females)~* Hyperlipidemia~* BMI \>30 kg /m2~* H/O excessive alcohol use~* Diabetes mellitus~* Congestive heart failure~* Ischemic heart disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Acitretin
- Experimental (Type: EXPERIMENTAL): Pioglitazone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Etoricoxib (Arcoxia) Taken Prophylactically to Prevent Ramadan Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 -65.~* Patients will be enrolled if they declared that they intended to complete the dawn to dusk Ramadan fast, and had demonstrated their commitment by doing so for the previous three years (unless medically prevented.)~* Patient states that he/she typically suffered from headache during fasting in the past.~Exclusion Criteria:~* Patients with a history of severe cardiovascular disease, diabetes, asthma, COPD, hypertension, or a history of bleeding, particularly in the gastrointestinal tract~* Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions after taking acetylsalicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors~* Pregnant or lactating patients. Sexually active women of childbearing age will be included only if using birth control~* Severe hepatic dysfunction~* Estimated renal creatinine clearance \<30 ml/min~* History of peptic ulcer, erosive gastritis, esophagitis or inflammatory bowel disease~* Congestive heart failure~* Patients with hypertension whose blood pressure is persistently elevated above 140/90mmHg and has not been adequately controlled Established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease~* Cancer or any other malignant disease~* History of medication overuse. Overuse of analgesics or antimigraine drugs according to the IHS criteria (chapter 8)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Etoricoxib First (Type: EXPERIMENTAL): This arm will receive etoricoxib for six days, followed by placebo for eight days.
- Etoricoxib Second (Type: EXPERIMENTAL): This arm will get placebo for eight days before beginning their fast, followed by etoricoxib for six days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trans-Nasal Maxillary Multi-Sinus Balloon Dilation Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Be at least age 18 years old or older.~2. Be a candidate for transnasal balloon dilation of the maxillary sinus(es) with or without balloon dilation of the frontal or sphenoid sinus(es) using XprESS consistent with the device's Indication for Use.~3. Have a sinus CT scan within 12 months of the procedure date.~4. Be able and willing to provide consent.~5. Be willing to comply with the protocol requirements.~Exclusion Criteria:~1. Have any prior maxillary sinus surgery (eg, antrostomy, uncinectomy).~2. Require any concomitant endoscopic sinus surgery (ESS) or nasal surgery (exception: turbinate reduction) at the time of the study procedure.~3. Have any nasal surgery (eg, septoplasty) or nonmaxillary sinus surgery (eg, frontal sinusotomy, sphenoidotomy, full/partial ethmoidectomy) performed within 3 months prior to enrollment.~4. Have presence of features consistent with sinus fungal disease.~5. Be allergic to nickel or barium sulfate.~6. Be currently participating in any other drug or device clinical studies excluding postapproval or marketing registry studies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- XprESS Multi-Sinus Dilation Tool (Type: EXPERIMENTAL): Balloon sinus dilation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Compare the Efficacy and Safety of a Combination Therapy of Ezetimibe and Rosuvastatin Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients (I-ROSETTE Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. 19 \~ 79 years old~2. Patients who confirmed hypercholesterolemia.~3. Patients who requiring drug therapy according to NCEP ATP(National Cholesterol Education Program Adult Treatment Panel) III Guideline at Visit2.~4. Patients with Triglyceride\< 400 at Visit 2.~5. Patients who have a wash-out period over 4 weeks for other drugs that can affect lipid profile.(Patients who have lipid regulators should have washout period over six weeks)~6. Patients who agreed to participate in the trial~Exclusion Criteria:~1. Patients who have a history of myopathy or rhabdomyolysis by statin treatment or hypersensitivity to statin HMG CoA(3-hydroxy-3-methylglutaryl-coenzyme) reductase inhibitors) or ezetimibe.~2. A heavy alcohol consumer. (alcohol \> 25 units/week)~3. Patients with severe renal disease. (creatinine ≥ 2.0 mg/dL)~4. Patients with active liver disease and AST(aspartate transaminase) or ALT(alanine transaminase) \> 2 times of upper limit of normal range.~5. Patients with CPK(creatine phosphokinase) \> 2 x upper limit of normal range.~6. Patients who have a endocrine or metabolic diseases known to affect the serum phospholipid or lipoprotein.~7. Patients with HIV(human immunodeficiency virus positive.~8. Patients who have a acute arteriopathy.~9. Patients with uncontrolled hypertension.~10. Patients who have hereditary problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.~11. Patients who have a drugs absorption disorder by gastrointestinal surgery or gastrointestinal disorder.~12. Patients with tumor.~13. Patients who have hormonal therapy.~14. Pregnancy or breastfeeding patients who don't agree to use adequate contraception.~15. Patients who are judged unsuitable to participate in this study by investigator.~16. Patients taking other clinical trial drugs within 30 days from the time of visit for screening.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- R5 (Type: ACTIVE_COMPARATOR): Rosuvastatin 5mg
- R10 (Type: ACTIVE_COMPARATOR): Rosuvastatin 10mg
- R20 (Type: ACTIVE_COMPARATOR): Rosuvastatin 20mg
- R5/E10 (Type: EXPERIMENTAL): Rosuvastatin 5mg/Ezetimibe 10mg
- R10/E10 (Type: EXPERIMENTAL): Rosuvastatin 10mg/Ezetimibe 10mg
- R20/E10 (Type: EXPERIMENTAL): Rosuvastatin 20mg/Ezetimibe 10mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Autologous Platelet Lysate in Corneal Epithelial Defects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Cognitive ability to understand and sign the consent form.~2. Corneal ulcers that did not re-epithelialise after 1 week of conventional treatment (therapeutic contact lenses, topical artificial tears, eye packs and antibiotic eye-drops).~3. Clinical indications: corneal ulcer due to caustic substances, corneal epitheliopathy, corneal lesions following cataract surgery, recurrent ulcerative keratitis, corneal lesions due to a foreign body.~4. Good compliance with the study regimen and availability for the duration of the entire study period.~Exclusion Criteria:~1. Corneal ulcers which developed tissue scars.~2. Pregnant or lactating women.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- Platelet Lysate (Type: EXPERIMENTAL): Autologous platelet lysate dispensed into eye droppers to be applied four times a day for a total of four weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Duration of Brace Wear in Clubfoot Treatment - A Prospective Randomized Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject \< 1 year of age when treatment initiated at local site~* Confirmed diagnosis of Isolated Clubfoot~* At least one foot demonstrates fixation of the foot in equinus, forefoot adduction, cavus and hindfoot varus~* Deformity was present at birth~Exclusion Criteria:~* Previous foot abduction bracing~* Previous surgical correction (excluding Tenotomy)~* Dysmorphic features, additional anomalies (i.e. congenital heart disease, hypospadias, a genetic syndrome), or developmental delay~* Neurologic cause for clubfoot (i.e. myelomeningocele or sacral agenesis)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 1 Year
- Healthy Volunteers: f

Study Arms:
- 4-Year Bracing Arm (Type: OTHER): This group has been randomized to 4 years of bracing after correction of clubfoot using the Ponseti Method.
- 2-Year Bracing Arm (Type: OTHER): This group has been randomized to 2 years of bracing after correction of clubfoot using the Ponseti Method.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete